By employing AI-assisted design to develop biologic drug candidates, our platform addresses the mostfundamental obstacles in immunotherapy. These candidates are designed to specifically target eithermalignant or autoimmune diseases.
We concentrate on multifunctional immunotherapy that has the potential to address the complexity ofthe tumor microenvironment (TME), which is characterized by complex interactions among cancer,immune, and normal cells. Our IL2Rβγc-biased IL2v was utilized to create a variety of antibody-cytokinefusion proteins (ACFPs). These proteins not only induce anticancer immunity but also demonstrate theability to inhibit immune checkpoints or target hypoxic tumor microenvironments (TMEs) or tumorantigens, such as Her2. KINE's ACFPs exhibited anticancer effects on a variety of murine tumor models incomparison to these control parental antibodies.
While our primary focus is cancer immunotherapy, we are also leveraging our AI-assisted protein designplatform to create immune-suppressing therapeutics, such as IL2Rα-biased IL2v, for autoimmune diseases.This expansion into immunomodulation presents novel opportunities for treating conditions thatnecessitate immune system regulation rather than stimulation.
© Copyright 2025. All Rights Reserved